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Introduction {#sec004}
============

*Streptococcus pneumoniae* are a common cause of relatively mild localized infections such as otitis media but can also cause more severe infections like pneumonia and live threatening invasive diseases. Penicillin is the antimicrobial of choice for patients infected with susceptible pneumococci \[[@pone.0230332.ref001]--[@pone.0230332.ref004]\]. Non-susceptibility to penicillin and other antimicrobials is common in many countries and may necessitate higher doses of penicillin, or broad-spectrum antimicrobial agents \[[@pone.0230332.ref005]--[@pone.0230332.ref007]\].

The epidemiology of penicillin non-susceptible pneumococci (PNSP) in Iceland has been studied intensively from 1988--2010 with emphasis on pneumococcal serotypes and antimicrobial susceptibility \[[@pone.0230332.ref008], [@pone.0230332.ref009]\]. Two PNSP epidemics have been described in the country prior to implementation of the 10-valent protein conjugate pneumococcal vaccine (PHiD-CV) into the country's childhood vaccination program in 2011. Both were caused by known multi-resistant international pneumococcal lineages, CC90, Spain^6B^-2 CC236/270/320, single and double locus variants of Taiwan^19F^-14. The 6B lineage was first detected in Iceland in 1988, peaked in 1995 and subsequently gradually declined, simultaneously in all age groups \[[@pone.0230332.ref008]\]. The 19F lineage was first detected in Iceland in 1998. It became the dominating PNSP lineage in the country in 2004 and peaked in 2010, the last year prior to the pneumococcal vaccination. At that time, the proportion of PNSP of all pneumococcal isolates from patients was 37.7% \[[@pone.0230332.ref009]\].

Many of the serotypes commonly resistant to antimicrobials are targeted by the PHiD-CV, including 19F. Pneumococcal vaccination can therefore lead to decreased prevalence of PNSP both in invasive and non-invasive diseases \[[@pone.0230332.ref010]--[@pone.0230332.ref012]\]. However, vaccination has little or no effect on the prevalence of total pneumococcal carriage due to serotype replacement \[[@pone.0230332.ref013], [@pone.0230332.ref014]\]. Accordingly, replacement with emerging PNSP of non-vaccine serotypes is a cause for concern \[[@pone.0230332.ref015]--[@pone.0230332.ref017]\].

The aim of the study was to describe the antimicrobial susceptibility and serotype distribution of PNSP in Iceland from the beginning of vaccination until end of 2017.

Materials and methods {#sec005}
=====================

Study population {#sec006}
----------------

All the pneumococcal isolates in the study were cultured and identified at the Department of Clinical Microbiology, Landspítali University Hospital, Reykjavík. The department serves as the primary microbiology laboratory for the greater capital area of Reykjavík. In 2011, 202,341 individuals lived in the capital area (i.e. 63.5% of the country population of 318,452), 9.0% were children less than six years old. In 2017, 216,878 individuals lived in the area (i.e. 64.1% of the country population of 338,349), 7.7% were children less than six years old (<http://www.statice.is/>). Patients from other parts of the country often seek health services in the capital and were included in the study. The laboratory also serves as a reference laboratory for the whole country. In total, it is estimated that the laboratory serves 85% of the population of the country for pneumococcal cultures and identifications.

Infant vaccination with PHiD-CV (Synflorix®) was initiated in April 2011 in Iceland in a 2-plus-1 schedule, without catch-up. Over 97% of Icelandic children born in 2011 and later had received the primary vaccine doses in 2015. The study population can be considered unvaccinated prior to the study period, as only 2.3% of children were vaccinated with a protein conjugated pneumococcal vaccine in 2010. The first year of the study, 2011, was used in this study as a baseline for the evaluation of vaccine effect. By December 2011 8.6% of children \<4 years of age had received ≥2 doses of PHiD-CV \[[@pone.0230332.ref018]\].

Bacterial isolates and samples {#sec007}
------------------------------

The study included all pneumococcal isolates identified at Landspítali in 2011--2017, except isolates from nasopharynx and throat. Repeat isolates of the same phenotype (same serotype and antibiogram) from the same patient within 30 days were excluded as they were considered to represent the same infection. The pneumococci were cultured and identified from routine patient specimens using conventional methods, i.e. plated on two 5% horse blood agar plates (Oxoid, Hampshare, UK), one incubated in a 5% CO~2~ and the other one anaerobically. Identification was done using optochin test (and bile solubility if unclear). All isolates from 2016--2017 were also identified with MALDI-Tof.

The patients were divided into five age groups: 0--1, 2--6, 7--17, 18--64 and ≥65 years old. The isolates were grouped according to the sampling site as follows: middle ear (ME: swabs and pus from middle ear, or otorrhoea), lower respiratory tract (LRT: sputum, bronchiolar lavage, pleural fluid), sterile body fluids (SBF: blood, cerebrospinal fluid and joint fluid) and other sampling sites (OSS: mostly specimens from conjunctiva and sinuses).

Antimicrobial susceptibility testing {#sec008}
------------------------------------

Disk diffusion susceptibility testing was performed on all the isolates using the EUCAST guidelines \[[@pone.0230332.ref019]\] except for the first year when the CLSI Performance Standard for Antimicrobial Disk Susceptibility Tests was used \[[@pone.0230332.ref020]\]. The isolates were screened for penicillin non-susceptibility with 1 μg oxacillin discs. Oxacillin sensitive (≥20 mm zone) isolates were defined as susceptible to penicillin and other β-lactams. The minimum inhibitory concentration (MIC) for penicillin and ceftriaxone was measured for all oxacillin resistant isolates (\<20 mm zone) using the E-test® (Solna, Sweden/bioMérieux, France) \[[@pone.0230332.ref021]\]. Non-susceptibility to penicillin was defined as penicillin MIC of \>0.06 mg/L. Disk diffusion susceptibility testing was also performed for chloramphenicol, erythromycin, clindamycin, tetracycline and trimethoprim/sulfamethoxazole. All susceptibility results were interpreted according to the EUCAST criteria for clinical breakpoints \[[@pone.0230332.ref022]\].

Serotyping {#sec009}
----------

Oxacillin resistant isolates were routinely screened for vaccine serotypes using agglutination with Pneumotest-Latex and/or latex antisera for specified serotypes or pools (Statens Serum Institute, Copenhagen, Denmark) \[[@pone.0230332.ref023]\]. Isolates that did not belong to vaccine serotypes were serotyped using PCR. The PCR was done as sPCR, or mPCR including a panel of all the serotypes included in the PHiD-CV and selected serotypes previously detected in our studies---serotypes 1, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9V, 9N, 10A, 10F, 11A, 12F, 14, 15A, 15B/C, 16F, 17F, 18A/B/C/F, 19A, 19B/C, 19F, 20A/B, 21, 22F, 23A, 23B, 23F, 24F, 29, 31, 33F,33B/D, 34,35B, 35F, 35(25F), 42 (35A/C), 47A \[[@pone.0230332.ref008], [@pone.0230332.ref009], [@pone.0230332.ref024]--[@pone.0230332.ref026]\]. Serogroup/serotype-specific primer pairs were used with primer pairs for *cps*A for the *cps* locus and *lyt*A for autolysin as internal controls. In addition, primers for *cps*B were used to confirm the absence of capsular genes, when *cps*A was negative \[[@pone.0230332.ref024], [@pone.0230332.ref027]--[@pone.0230332.ref030]\]. Serotypes of serogroup 6 were identified using previously described PCR methods \[[@pone.0230332.ref031]--[@pone.0230332.ref033]\]. Vaccine serotypes (VT) were defined as the serotypes targeted by the PHiD-CV. Non-vaccine serotypes (NVTs) were defined as serotypes not targeted by the PHiD-CV. Isolates were defined as non-encapsulated *S*. *pneumoniae* (NESp) when they were PCR positive for *lyt*A and negative for the capsular genes *cps*A and *cps*B \[[@pone.0230332.ref024], [@pone.0230332.ref026]\].

Statistical analysis {#sec010}
--------------------

Statistical analyses were done using Fisher´s exact and chi-square tests. Statistical significance was set at p≤0.05.

Ethics statement {#sec011}
----------------

The study was approved by The National Bioethics Committee (VSNb2013010015/03.07) and the appropriate authorities at the Landspitali University Hospital, Iceland. The samples were bacterial isolates and all patient data were fully anonymized before being analysed. The National Bioethics Committee waived the requirement for informed consent.

Results {#sec012}
=======

Demographics {#sec013}
------------

From 2011--2017, the laboratory received a total of 87,374 samples for culture from ME (4,868), LRT (13,633) and SBF (68,873). The total number of pneumococcal isolates from these samples that met the study criteria was 1,728. One patient with multiple identical isolates, within the two last years of the study, was considered an outlier and his repeated isolates excluded. A few isolates had not been stored or did not survive storage, making the number of available isolates for the study 1,706 (98.7%). The annual number of pneumococcal isolates decreased gradually with time, from 348 isolates in 2011 to 163 in 2017 (p\<0.0001).

ME samples were 4,868 and their annual number decreased significantly during the study period. At the same time the proportion of samples with pneumococci decreased from 191/950 (20.1%) in 2011 to 36/504 (7.1%; p\<0.0001) in 2017. Samples from LRT were 13,633 in total and their annual number increased significantly with time. At the same time the number of pneumococcal isolates remained relatively stable resulting in decreased proportion of samples with pneumococci, 85/1,676 (5.1%) in 2011 and 85/2,356 (3.6%; p = 0.03) in 2017. Samples from SBF were 68,873 and their annual number increased significantly. At the same time the proportion of samples with pneumococci decreased from 31/8,817 (0.4%) to 24/11,908 (0.2%). Information on the number of samples from OSS was not available, but the number of pneumococcal isolates detected decreased from 41 in 2011 to 18 in 2017 ([Fig 1](#pone.0230332.g001){ref-type="fig"} and [S1 Table](#pone.0230332.s001){ref-type="supplementary-material"}).

![Annual numbers of PNSP of vaccine serotypes, PNSP of non-vaccine serotypes and susceptible pneumococcal isolates according to sampling site.\
In each cumulative column, the PNSP of VTs are shown in the darkest color at the bottom, the PNSP of NVTs in lighter color in the middle area and the PSP in the lightest color at the top of the columns. The colors differ to differentiate the sampling site presented, red for middle ear, yellow for lower respiratory tract, green for sterile body fluids and blue for other sampling sites.](pone.0230332.g001){#pone.0230332.g001}

Pneumococcal isolates from the youngest age group, 0--1 years old children were 523 (of the total 1706 isolates, 30.7%) and 422/523 (80.7%) originated from ME. In 2011 the number of isolates from this age group was 154/348 (44.3%) and significant reduction was already seen in 2012 when the number of isolates were 109/322 (33.3%; p = 0.007). Gradual decline continued through the remaining period to become 12/163 (30.7%) in 2017. Isolates from the oldest age group, ≥65 years old patients, were 393/1706 (23.0%) and 284/393 (72.3%) were from LRT. There was a non-significant decline in the numbers with time, 56 isolates in 2011 and 37 in 2017 (p = 0.08; [Fig 2](#pone.0230332.g002){ref-type="fig"} and [S2 Table](#pone.0230332.s002){ref-type="supplementary-material"}).

![Annual numbers of PNSP of vaccine serotypes (VT), PNSP of non-vaccine serotypes (NVT) and susceptible pneumococcal isolates (PSP) according to age groups.\
In each cumulative column, the PNSP of VTs are shown in the darkest color at the bottom, the PNSP of NVTs in a lighter color in the middle area and the PSP in the lightest color at the top of the columns. The colors differ to differentiate the age group presented, red for 0--2, yellow for 2--6, green for 7--17, blue for 18--64 and grey for ≥65 years old.](pone.0230332.g002){#pone.0230332.g002}

Susceptibility {#sec014}
--------------

The number of PNSP was 516 (of the total of 1,706 pneumococcal isolates, 30.2%). In 2011 the number of PNSP was 143/348 (41.1%) and decreased to 42/202 (20.8%; p\<0.0001) in 2014, but then increased to 54/163 (33.1%) in 2017 (p = 0.009; [S1 Table](#pone.0230332.s001){ref-type="supplementary-material"}).

Temporal changes were observed in the penicillin MIC values of the PNSP with an increase in the proportion of isolates belonging to the intermediate susceptibility category that had relatively low MIC values, most often \>0.06--0.5 mg/L, but a decrease in the proportion of isolates with higher MIC values. In 2011, 14/143 (9.8%) isolates had penicillin MIC value of \>0.06--0.5 mg/L, 97/143 (67.8%) of \>0.5--2.0 mg/mL and 32/143 (22.4%) of \>2.0 mg/L. In 2017 the numbers were 39/54 (72.2%; p\<0.0001) isolates, 13/54 (24.1%; p = 0.0001) and 2/54 (3.7%; p = 0.001), respectively ([Fig 3](#pone.0230332.g003){ref-type="fig"}).

![The MIC values (mg/L) of all 1,706 pneumococcal isolates according to years.\
Oxacillin sensitive and isolates with confirmed penicillin MIC of ≤0.06 mg/L were defined as sensitive; intermediate with relatively low MIC values, \>0.06--0.5 mg/L; intermediate with relatively high MIC values, \>0.5--2.0 mg/L; and resistant isolates with penicillin MICs of \>2.0 mg/L.](pone.0230332.g003){#pone.0230332.g003}

Of the PNSP isolates, 16/516 (3.1%) were susceptible to all routinely tested antimicrobials other than penicillin, 51/516 (9.9%) were non-susceptible to two antimicrobial classes and 449/516(87.0%) were multi-resistant (non-susceptible against three or more antimicrobial classes). Most of the PNSP isolates, 333/516 (64.5%), were non-susceptible to five antimicrobial classes. Of the multi-resistant isolates, 311/449 (69.3%) were of serotype 19F. This number decreased with time from 122/134 isolates in 2011 (91.0%) to 15/41 in 2017 (36.6%; p\<0.0001; [Fig 4](#pone.0230332.g004){ref-type="fig"}).

![Annual number and proportions of non-susceptible pneumococcal isolates to routinely tested antimicrobials.\
Numbers of non-susceptible isolates to the antimicrobials are shown on the left Y-axis: clindamycin (DA) chloramphenicol (C), erythromycin (E), penicillin (P), trimethoprim/sulfamethoxazole (SXT) and tetracycline (TE).The proportions of PNSP of all pneumococci are shown in percentages on the right Y-axis (red dotted line).](pone.0230332.g004){#pone.0230332.g004}

PNSP isolates from the youngest age group, children 0--1 year old, were 179/516 (34.7%). The annual number and proportion decreased from 88/143 (61.5%) isolates or 1172.1 isolates/100,000 inhabitants in 2011 to 4/44 (9.1%) in 2015, then increased again to 12/54 (22.2%), or 194.9 isolates/100,000 inhabitants in 2017 (difference between 2011 and 2017, p\<0.0001). The large majority originated from ME, 170/179 (95.0%). Two isolates were from SBF, one in 2011 and the other in 2016. PNSP isolates from the oldest age group, ≥65 years old, were 122/516 (23.6%), or 69.6/100,000 inhabitants, highest at 23/42 in 2015 (54.7%) and lowest at 12/54 (22.2%), or 35.8/100,000 inhabitants in 2017 (p = 0.001). The majority originated from LRT, 105/122 (86.1%; [S2 Table](#pone.0230332.s002){ref-type="supplementary-material"}).

PNSP serotypes {#sec015}
--------------

PNSP isolates of VTs were 362/516 (70.2%) and of NVTs 154/516 (29.8%). The number of isolates of VTs decreased with time, 132/143 (92.3%) in 2011 and 17/54 (31.5%) in 2017 (p\<0.0001), while the number of isolates of NVTs increased from 11/143 (7.7%) in 2011 to 37/54 (68.5%) in 2017 (p\<0.0001). The number of VT isolates decreased in all age groups, but first and most in the youngest children. In 2011, 85/88 (96.6%) of the PNSP in children 0--1 years old were of VTs, or 1132.1/100,000 inhabitants. In 2012 28/35 (80.0%) isolates, or 395.0/100,000 inhabitants, (p = 0.006) and in 2017, 2/12 (16.7%), or 32.5/100,000 inhabitants.

The most common serotype was 19F, 317/516 (61.4%) isolates, accounting for 87.6% of the PNSP isolates of VTs. Their number was highest in 2011, 124/143 (86.7% of PNSP), lowest in 2016, 13/55 (23.6%; p\<0.0001) and were 15/54 (27.8%) in 2017. Repeated isolation of 19F with more than 30 days intervals was detected in 41 patients and the majority 28/41 (68.3%) had one repetition ([Fig 5](#pone.0230332.g005){ref-type="fig"} and [S3 Table](#pone.0230332.s003){ref-type="supplementary-material"}).

![Annual numbers of PNSP isolates of vaccine and non-vaccine serotypes and their four most common serotypes.\
The total number of isolates of vaccine serotypes is presented by blue dotted line and of non-vaccine serotypes by green dotted line. The most common PNSP serotype was 19F, followed by 6C, non-encapsulated *Streptococcus pneumoniae* (*lyt*A positive and *csp*A and *csp*B negative) ranked third and 6B fourth.](pone.0230332.g005){#pone.0230332.g005}

PNSP isolates of serotype 19F from children 0--1 years old were 81/88 (92.1%) in 2011 and 1/12 (8.3%) in 2017 (p \<0.0001), while in patients ≥65 years old they were 12/19 (63.2%) and 6/12 (50.0%), respectively (p = 0.71).

Other PNSP VTs identified were serotype 6B with 26/516 (5.0%) isolates, serotype 14 with 12/516 (2.3%), serotype 23F with 6/516 (1.2%) and 9V with 1/516 (0.2%) isolates.

PNSP isolates of NVTs were 154/516, 11/143 (7.7%) in 2011 and 37/163 (68.5%, p = 0.0003) in 2017. The most common serotype was 6C, 34/516 (6.6%) isolates, which increased with time. One isolate was detected in 2011, but 10/54 (18.5%) in 2017 (p\<0.0001). All the isolates were multi-resistant with the following antibiogram: intermediate to penicillin with MIC of 0.094--0.125 mg/L, resistant to erythromycin, clindamycin and tetracycline, but susceptible to sulfa-trimethoprim and chloramphenicol. The second most common NVT was serotype 15A with 17/516 (3.3%) isolates, increasing with time. All the 15A isolates were multi-resistant and had similar antibiograms as the serotype 6C isolates. The third was serotype 19A with 15/516 (2.9%) isolates, 1--4 isolates per year over the study period. Non-encapsulated S. pneumoniae (NESp) isolates were 33 (6.4%), their number fluctuated with time from 2--8 isolates a year. All the NEsp isolates originated from adults except one from a 12 years old child, 30 of the isolates were from the LRT and three from conjunctiva.

Discussion {#sec016}
==========

Penicillin non-susceptible pneumococci of vaccine serotypes have virtually disappeared from children with pneumococcal diseases after the implementation of the protein conjugate pneumococcal vaccine into the childhood vaccination program in Iceland. Moreover, a clear herd effect was observed in other age groups, but least in the oldest patients.

Our group has shown in another recent study that nasopharyngeal carriage of PNSP of VTs has become rare in children since pneumococcal vaccination was initiated while pneumococcal carriage rates have not changed \[[@pone.0230332.ref024]\]. As carriage is the prerequisite for pneumococcal infections \[[@pone.0230332.ref034], [@pone.0230332.ref035]\] and as the nasopharynx of children is the main source of pneumococci \[[@pone.0230332.ref036], [@pone.0230332.ref037]\] these findings complement each other.

In 2011, the first year of the study, the proportion of PNSP was higher than ever before in Iceland. This peak was caused by the multi-resistant 19F lineage, more than nine out of ten PNSP isolates belonged to 19F that emerged as a dominating PNSP serotype in 2004 \[[@pone.0230332.ref009]\] Almost all of the remaining PNSP isolates in that year were of VTs. In the last year of the study, 2017, the number of PNSP isolates of VTs was only a fraction of the initial number with also a strong decrease in the total number of pneumococcal isolates. Isolates of serotype 19F were still the majority of PNSP of VT, although only a fraction of their number in 2011, all originating from adults except one. Isolates of other VTs in 2017 were one isolate each of serotype 6B and 14. These findings strongly demonstrate the important effect of the vaccination to reduce PNSP in children and in adults. The fact that the PNSP serotypes were initially more or less all of VTs, facilitated this dramatic change. However, serotype replacement with PNSP of NVT in the last years of the study is a cause of concern.

The decreased prevalence of PNSP was already apparent in children 0--1 year old in the second year of the study. By that time the number of PNSP isolates of VTs had decreased by more than a half from the first year. This reflects a reduction of acute otitis media following vaccination as described by Sigurdsson *et*. *al*. \[[@pone.0230332.ref038]\]. The reduction was mostly due to decreased prevalence of the multi-resistant serotype 19F of the CC236/270/320 lineage as described by Quirk *et*. *al*. \[[@pone.0230332.ref024], [@pone.0230332.ref026]\]. The reduction of PNSP after pneumococcal vaccine was as expected as most of the PNSP isolates in the era prior to vaccination belonged to VTs \[[@pone.0230332.ref010], [@pone.0230332.ref039]\]. In the last year of the study, PNSP of VTs were identified only in three children under the age of seven years. Isolates of serotype 19F were cultured from ME samples from two children, aged one and two years, both were outpatients and their immune and vaccine status unknown. The third isolate was of serotype 14 identified from blood culture of a fully vaccinated, chronically ill one year old child. A few incidents with PNSP of VTs could be expected, neither the efficacy of the vaccine, nor the participation and compliance to the vaccination program was absolute.

Towards the end of the study period, a significant decrease in PNSP of VTs in patients 18--64 years of age had become apparent, while the incidence of NVTs increased. This finding strongly indicates herd effect in this age group. The decrease in PNSP of VTs compared to increase of NVT in patients ≥65 years was not significant according to the number of pneumococcal isolates. However, a significantly fewer samples from this age group included isolates of VTs in the last years of the study compared to the first.

The most prominent PNSP of non-vaccine serotypes emerging after vaccine initiation were serotypes 6C and 15A. Both were usually multi-resistant, but had lower penicillin MIC values than the multi-resistant 19F lineage, explaining the reduction in penicillin MIC values with time. PNSP of serotype 19A were seen on few occasions without changes in prevalence during the study period and were not regarded problematic as has been described in other studies \[[@pone.0230332.ref040]--[@pone.0230332.ref042]\]. Isolates of serotype 6A were rarely seen but remained stable throughout the study period \[[@pone.0230332.ref043]\]. The emergence of serotypes 6C and 15A has been described in several countries and their emergence in Iceland calls for close monitoring \[[@pone.0230332.ref044]--[@pone.0230332.ref047]\].

Interestingly NESp were not found in children while they were among the most common pneumococci in adults. This is in contrast to findings of other investigators who have reported increase in children after initiation of vaccination \[[@pone.0230332.ref048], [@pone.0230332.ref049]\]. In an earlier study of our group a large proportion of the isolates were analysed using whole genome sequencing, confirming the identification and the absence of the capsule \[[@pone.0230332.ref026]\].

The effect of the financial crisis that started in Iceland in 2008 had an impact on the number of samples sent for culture. This made statistical analysis more complex, which might be considered a weakness. At the beginning of the study, physicians were still being advised to reduce diagnostic testing as much as possible. When the economic situation began to improve, around 2014, the number of samples increased to similar levels as before the crisis, then gradually increased over the last years of the study except for ME samples that continued to decline. This decline of ME samples reflects the effect of the vaccination reducing otitis media incidence in children \[[@pone.0230332.ref018], [@pone.0230332.ref050]\]. Focusing on the proportion of PNSP is not sufficient to describe the changes taking place after vaccination. The reduction of PNSP of VTs in LRT and SBF appear to be less according to the numbers of detected pneumococcal isolates rather than to the numbers of cultured samples. This affects the evaluation of the herd effect in adults, as almost all LRT samples (95%) originated from adults. On the other hand, almost all ME samples (95%) were from children, while SBF samples reflected a broader age group, or the risk groups for invasive disease.

The continued surveillance of PNSP since they were first detected in Iceland in 1988 makes this study unique. The results demonstrate the situation for all age groups, virtually for the whole population for three decades. The vaccination has made a substantial impact on the rate of PNSP. However, emerging resistant non-vaccine serotypes are of concern and demands continued monitoring of PNSP.
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Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors presented interesting data, regarding the epidemiology of pneumococcal infections and the evolution of antimicrobial resistance, after the introduction of a conjugate vaccine. However, here seem to be some aspects that need further clarification:

1\. Materials and Methods: the authors should explain the method of identification of S. pneumoniae in cultures.

2\. Materials and Methods, line 89: "serotyping was done using agglutination with Pneumotest-Latex and/or latex antisera for specified serotypes or pools and/or PCR" -- why? Which serotypes were detected by each of the methods?

3\. Materials and Methods, line 97: isolates defined as non-encapsulated when positive for lytA and negative for capsular genes. There are other streptococcal species carrying the lytA gene. Did the authors confirmed by any other method the identification of these isolates? Furthermore, non-encapsulated isolates ranked third among NVT(n=34), so this should be clarified.

4\. Results, line 153: the number of PNSP changed from 41.1% in 2011 to 20.8% in 2014, but then increased again to 33.1% in 2017. Is the whole period, is really there a decreasing trend? As this is the main message of the paper, I believe it should be further discussed. Furthermore, the dynamics of the serotypes can add extra discussion to this, since the 19F isolates, the main serotype contributing to resistance, decreased form 2011 to 2016, but then increased again in 2017.

5\. Analysis of figure 1 seems to suggest that vaccination was more effective in decreasing the proportion of middle ear infections than that of LRT infections. Can the authors please comment on this?

Reviewer \#2: The authors describe changes in PNSP in Iceland from 2011-2017 post PCV-10 introduction. Overall the paper is well written, and results described and discussed is in a clear, concise manner.

Specific comments

Abstract. Last paragraph. "linage" should be "lineage"

Line 48-57. The paper describes changes in PNSP as percentages of cases throughout the paper. You include population denominators in your methods section. Your population sizes are similar for 2011 and 2017 but showing annual incidence (number of cases/100,000 population) would be a better comparison for showing differences over time.

Line 72. Interesting that you included pleural fluid in the LRT group. Why not as sterile body fluid?

Line 74. Isolates from "sinuses"? You excluded nasopharynx and throat but kept in sinuses? Why?

Line 159. I assume \>0.6-0.5 mg/L should be \>0.06-0.5 mg/L?

Fig 3, Please correct your lower values from 0.6 to 0.06 in the legend as well as in the figure.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230332.r002

Author response to Decision Letter 0

16 Jan 2020

Response from the authors to the reviewers

Journal Requirements

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response

The manuscript has been formatted according to PLOS ONE´s style requirements.

The names of institutions have been amended according to PLOS requirements as follows:

Faculty of Medicine, University of Iceland, Reykjavík, Iceland

Department of Clinical Microbiology, Landspitali University Hospital, Reykjavík, Iceland

BioMedical Centre of the University of Iceland, Reykjavik, Iceland

Children´s Hospital Iceland, Landspitali University Hospital, Reykjavík, Iceland

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response

Captions for our supporting information have been included at the end of the manuscript as follows:

S1 Table. Annual numbers and proportions of samples, total number of pneumococcal isolates, penicillin non-susceptible pneumococci (PNSP) and there of vaccine serotypes (VT) and non-vaccine serotypes (NVT), all according to sampling site.

S2 Table. Annual numbers and proportions of samples, total number of pneumococcal isolates, penicillin non-susceptible pneumococci (PNSP) and there of vaccine serotypes (VT) and non-vaccine serotypes (NVT), all according to age groups.

S3 Table. The ten most common serotypes of penicillin non-susceptible pneumococci (PNSP) in 2011-2017 and non-encapsulated (NESp) PNSP. Other are the remaining 16 serotypes that were detected in ≥5 isolates each during the study period. All of these are non-vaccine serotypes except for one isolate of 9V in 2011.

3\. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

Response

Additional information about samples and ethics was included as follows:

The samples were bacterial isolates and all patient data was fully anonymized before being were analysed. The National Bioethics Committee waived the requirement for informed consent.

4\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

Response

The ethics statement has been written as separate sub chapter in the Material section as follows:

Ethics statement

The study was approved by The National Bioethics Committee (VSNb2013010015/03.07) and the appropriate authorities at the Landspitali University Hospital, Iceland. The samples were bacterial isolates and all patient data was fully anonymized before being analysed. The National Bioethics Committee waived the requirement for informed consent.

5\. Please amend your manuscript to include your abstract after the title page.

Response

The abstract has been included directly after the title page.

6\. Thank you for stating the following in the Competing Interests section:

This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) <https://www.landspitali.is>

\- GlaxoSmithKline Biologicals SA (KGK, HE, ÁH), <https://www.gsk.com>

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We note that you received funding from a commercial source: GlaxoSmithKline Biologicals SA

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors

Response

The Competing Interest Section now reads as follows:

This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) <https://www.landspitali.is>

\- GlaxoSmithKline Biologicals SA <https://www.gsk.com>

The authors declare that this does not alter our adherence to PLOS ONE policies on sharing data and materials. Neither GlaxoSmithKline Biologicals SA, nor Landspítali University Hospital Research Fund had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Response to reviewer \#1

1\. Materials and Methods: the authors should explain the method of identification of S. pneumoniae in cultures.

Response

We agree and added text after the first sentence in the chapter Bacterial isolates and samples as follows (line 99 in manuscript with track changes):

The pneumococci were cultured and identified from routine patient specimens using conventional methods, i.e. plated on two 5% horse blood agar plates (Oxoid, Hampshare, UK), one incubated in a 5% CO2 and the other one anaerobically. Identification was done using optochin test (and bile solubility if unclear). All isolates from 2016-2017 were also identified with MALDI-Tof.

2\. Materials and Methods, line 89: "serotyping was done using agglutination with Pneumotest-Latex and/or latex antisera for specified serotypes or pools and/or PCR" -- why? Which serotypes were detected by each of the methods?

Response

We agree that this needs clarification and amended Material and Methods as follows (line 122 in manuscript with track changes):

Oxacillin resistant isolates were routinely screened for vaccine serotypes using agglutination with Pneumotest-Latex and/or latex antisera for specified serotypes or pools (Statens Serum Institute, Copenhagen). Isolates that did not belong to vaccine serotypes were serotyped using PCR.

3\.

Materials and Methods, line 97: isolates defined as non-encapsulated when positive for lytA and negative for capsular genes. There are other streptococcal species carrying the lytA gene. Did the authors confirm by any other method the identification of these isolates? Furthermore, non-encapsulated isolates ranked third among NVT(n=34), so this should be clarified.

Response

During the last two years of the study, MALDI-Tof was used in addition to optochin testing for species identification. In an earlier study of our group (Quirk 2019), a large proportion of the isolates were analysed using whole genome sequencing, confirming the identification and the absence of the capsule.

Following information was added to the results (line 269 in manuscript with track changes):

All the NEsp isolates originated from adults except one from a 12 years old child, 30 of the isolates were from the LRT and three from conjunctiva.

Following text was added to the discussions directly after discussion of NVTs (line 324 in manuscript with track changes):

Interestingly NESp were not found in children while they were among the most common pneumococci in adults. This is in contrast to findings of other investigators who have reported an increase in children after initiation of vaccination (Takeuchi 2019, Keller 2016). In an earlier study of our group a large proportion of the isolates were analysed using whole genome sequencing, confirming the identification and the absence of the capsule (Quirk 2019).

4\. Results, line 153: the number of PNSP changed from 41.1% in 2011 to 20.8% in 2014, but then increased again to 33.1% in 2017. Is the whole period, is really there a decreasing trend? As this is the main message of the paper, I believe it should be further discussed. Furthermore, the dynamics of the serotypes can add extra discussion to this, since the 19F isolates, the main serotype contributing to resistance, decreased from 2011 to 2016, but then increased again in 2017.

Response

The increase in PNSP during the last years of the study are due to increase in NVTs, mainly due to an increase in prevalence of 6C and 15A. The dominating serotype in 2011 was 19F that constantly decreased to 13 isolates in 2016 and their number was 15 in 2017. Of the isolates in 2016 and 2017, two isolates originated from children each year all the other were from adults. We do not know the vaccine status of the children and no change in vaccination recommendations for adults was implemented where the serotype still lingered. We cannot speculate on this low increase of 19F in 2017 as their numbers are so low in 2016 and 2017, but we agree that this needs clarification.

Following sentences sentencewereadded in the discussion (line 290 in manuscript with track changes):

Isolates of serotype 19F were still the majority of PNSP of VT, although only a fraction of their number in 2011, all originating from adults except one. Isolates of other VTs in 2017 were one isolate each of serotype 6B and 14.

5\. Analysis of figure 1 seems to suggest that vaccination was more effective in decreasing the proportion of middle ear infections than that of LRT infections. Can the authors please comment on this?

Response

The difference can be explained by the difference in the age of the patients. Otitis media is much more common in children. Accordingly, most of the ME samples originate from children. On the other hand, it is difficult to obtain samples from the LRT of small children and pulmonary infection is relatively common in the oldest patients. Accordingly, most of the lower respiratory tract samples originate from adults. A herd effect from the vaccination of children can explain the reduction that is later seen in LRT isolates.

Reviewer \#2

1\. Abstract. Last paragraph. "linage" should be "lineage"

Response

The authors thank for this comment and have made appropriate correction.

2\. Line 48-57. The paper describes changes in PNSP as percentages of cases throughout the paper. You include population denominators in your methods section. Your population sizes are similar for 2011 and 2017 but showing annual incidence (number of cases/100,000 population) would be a better comparison for showing differences over time

Response

The authors agree and thank for this comment. We have added the number of isolates of PNSP/100,000 inhabitants and the number of isolates of VTs of PNSP/100,000 inhabitants to supplementary table 2 and added this information into the results as appropriate (lines 223-228 and 26-238 in manuscript with track changes):

3\. Line 72. Interesting that you included pleural fluid in the LRT group. Why not as sterile body fluid?

Response

We agree that pleural fluid is often included in sterile body fluids, however we have considered these LRT samples in our other studies and decided to do the same here.

4\. Line 74. Isolates from "sinuses"? You excluded nasopharynx and throat but kept in sinuses? Why?

Response

The authors excluded samples from nasopharynx for two reasons. The first being that during the study period, recommendations to physicians to send nasopharyngeal swabs changed. In the first years no specific recommendations were set, while in the later years the recommendation to physicians were to only send nasopharyngeal swabs from patients with treatment failure after using recommended antimicrobial prescriptions, or from patients with previously known antimicrobial resistant pneumococcal infection. The second reason is that samples from nasopharynx do not distinguish between carrier state and infection. On the other hand, samples from sinuses are mainly taken by otorhinolaryngologists in suspected infection (sinusitis).

5\. Line 159. I assume \>0.6-0.5 mg/L should be \>0.06-0.5 mg/L?

Fig 3, Please correct your lower values from 0.6 to 0.06 in the legend as well as in the figure.

Response

The authors thank for this comment and have made appropriate corrections.
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Submitted filename: Hjalmarsdottir_Response to reviwers.docx

###### 

Click here for additional data file.
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23 Jan 2020

PONE-D-19-30435R1

Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland

PLOS ONE

Dear Professor Hjálmarsdóttir,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We invite you to submit a revised version of the manuscript that addresses all the important points raised by the reviewer.

We would appreciate receiving your revised manuscript by Mar 08 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jose Melo-Cristino, M.D., Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In the response to the reviewers, the authors agreed that it was important to discriminate which serotypes were detected by each of the methods. In the revised version, the authors stated that "Isolates that did not belong to vaccine serotypes were serotyped using

PCR. The PCR was done as sPCR, or mPCR including a panel of all the serotypes included in the PHiD-CV and selected serotypes previously detected in our studies" -- this is contradictory and needs further clarification.

It is clear that the authors identified vaccine serotypes, but among the others, only some were detected, while others were simply classified as NVT. I believe it would be important to know which NVT can the authors identify by the methods used, since one of the main messages of the paper is "NVT in the last years of the study is a cause of concern". For example, serotype 8 is a NVT emerging in adult IPD in some countries, and the authors never mentioned this serotype. Is it absent from the collection or is simply not included in the serotyping scheme? Additionally, serotypes 35B and 11A have been associated with PNSP, but seem to be also absent from your collection, but they could also be not included in the scheme. I believe this should be clarified, because it is important to know which NVT are increasing.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230332.r004

Author response to Decision Letter 1

26 Feb 2020

Response to reviewer \#1

In the response to the reviewers, the authors agreed that it was important to discriminate which serotypes were detected by each of the methods. In the revised version, the authors stated that "Isolates that did not belong to vaccine serotypes were serotyped using PCR. The PCR was done as sPCR, or mPCR including a panel of all the serotypes included in the PHiD-CV and selected serotypes previously detected in our studies" -- this is contradictory and needs further clarification.

It is clear that the authors identified vaccine serotypes, but among the others, only some were detected, while others were simply classified as NVT. I believe it would be important to know which NVT can the authors identify by the methods used, since one of the main messages of the paper is "NVT in the last years of the study is a cause of concern". For example, serotype 8 is a NVT emerging in adult IPD in some countries, and the authors never mentioned this serotype. Is it absent from the collection or is simply not included in the serotyping scheme? Additionally, serotypes 35B and 11A have been associated with PNSP, but seem to be also absent from your collection, but they could also be not included in the scheme. I believe this should be clarified, because it is important to know which NVT are increasing.

Response

The authors misunderstood the reviewer's comment. We realise this now and agree that the article will benefit from including information on the results from serotyping of all PNSP isolates. For that purpose, we have amended Supplementary table 3 and it now includes these results. Furthermore, we have added a list of all serotypes included in the mPCR panel to the chapter material and methods in lines 124-127 of the manuscript as follows:

The PCR was done as sPCR, or mPCR including a panel of all the serotypes included in the PHiD-CV and selected serotypes previously detected in our studies - serotypes 1, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 7F, 8, 9V, 9N, 10A, 10F, 11A, 12F, 14, 15A, 15B/C, 16F, 17F, 18A/B/C/F, 19A, 19B/C, 19F, 20A/B, 21, 22F, 23A, 23B, 23F, 24F, 29, 31, 33F,33B/D, 34,35B, 35F, 35(25F), 42 (35A/C), 47A \[8, 9, 24-26\].

Six isolates were positive in lytA, cpsA and cpsB PCRs but negative in the serotype specific PCRs, this is also clarified in the table. Four isolatets of serogroup 15 and two isolates positive to pool G were further serotyped using PCR. The isolates of serogroup 15 were of serotype 15A and the isolates belonging to pool G were of serotype 35B. This was amended in the table and in the manuscript where lines 265-267 now read as follows:

The second most common NVT was serotype 15A with 17/516 (3.3%) isolates, increasing with time. All the 15A isolates were multi-resistant and had similar antibiograms as the serotype 6C isolates. The third was serotype 19A with 15/516 (2.9%) isolates, 1-4 isolates per year over the study period.

Regarding the reviewer's comment on serotype 8, it is included in the mPCR panel but no isolate of serotype 8 was detected. Only two isolates of serotype 11A were detected, but serotype 35B ranks number ten of PNSP serotypes.

The title of supplementary table 3 has been amended as follows:

Annual distribution of pneumococcal serotypes and non-encapsulated Streptococcus pneumonia (NESp) defined as penicillin non-susceptible pneumococci (PNSP) in 2011-2017, number of isolates (n) and proportions (%).
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Dear Dr. Hjálmarsdóttir,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jose Melo-Cristino, M.D., Ph.D.
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